Comparing qSMI and qCEUS for assessing vascularization in uterine cervical cancer: operable versus non-operable group

TL;DR

This study compares two ultrasound techniques for assessing blood vessel growth in cervical cancer, finding both effective but one potentially more convenient.

Contribution

The study introduces a direct comparison of qSMI and qCEUS for cervical cancer vascularization assessment, highlighting their predictive performance.

Findings

Non-operable cervical cancer showed higher vascularization metrics compared to operable cases.

qSMI's vascular index strongly correlates with qCEUS parameters like peak intensity and area under the curve.

qSMI demonstrated better predictive accuracy for treatment-group assignment than qCEUS.

Abstract

The present study aimed to compare the effectiveness and reliability of quantified superb microvascular imaging (qSMI) and quantified contrast-enhanced ultrasonography (qCEUS) in assessing vascularization in both operable and non-operable uterine cervical cancer.

A case-control study included 64 patients with pathology-proven and untreated cervical cancer, who underwent transvaginal ultrasonography combined with qSMI and qCEUS between January 2022 and June 2023. SMI results were quantified as the vascular index (VI), which were compared to 12 quantitative parameters of CEUS calculated with time-intensity curves (TIC).

According to FIGO staging and different treatment regimens, 64 patients with cervical cancer were divided into operable group (IA ~ IIA, n = 19) and non-operable group (IIB ~ IV, n = 45). In comparison to the operable group, the non-operable group showed significantly higher values in VI, peak intensity (PI), area under the curve (AUC), wash-in area (iAUC), wash-out area (oAUC), wash-in rate (WiR), mean intensity (Mean Int), and standard deviation (STD) (all P < 0.05). VI demonstrated strong correlations with CEUS parameters, notably PI (r = 0.854, P < 0.001) and AUC (r = 0.635, P < 0.001). Furthermore, VI showed a better predictive performance for treatment-group assignment than qCEUS parameters, with an 80.7% accuracy, 64.4% sensitivity and 89.5% specificity.

Both qSMI and qCEUS exhibit significant and comparable utility in detecting microvascular hyperplasia and predicting treatment-group assignments in cervical cancer. Furthermore, qSMI may offer added convenience in implementation.

Figures